Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.21 ▼ -2.08
(-90.82%)
MKT CAP: $165.6M • VOL: 68.11M
52W L $0 52W H $4
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
ABOS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$123.8M | -$114.0M | -$61.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$121.3M | -$102.3M | -$52.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$115.5M | -$86.2M | -$43.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$115.5M | -$86.2M | -$43.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $54.0M | $35.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $70.4M | $181.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABOS.